IP Library Granted Patent US 11,098,347
Granted Patent B2
US 11,098,347 · App. 15/322,000 · Granted Aug 24, 2021

Nucleic acid amplification device, nucleic acid amplification method, and chip for nucleic acid amplification

Inventors: Hidenori Nagai (Ikeda, JP); Shunsuke Furutani (Ikeda, JP); Yoshihisa Hagihara (Ikeda, JP); Yusuke Fuchiwaki (Takamatsu, JP)
Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY; KYORIN Pharmaceutical Co., Ltd.
C12Q1/686B01L3/502715B01L7/525C12M1/00C12N15/09C12Q1/6851B01L2300/0654B01L2300/0883B01L2400/0475Y02A40/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,347
App. No.
15/322,000
Granted
Aug 24, 2021
Kind
B2
Abstract

The present invention provides a reciprocal-flow-type nucleic acid amplification device comprising: heaters capable of forming a denaturation temperature zone and an extension/annealing temperature zone; a fluorescence detector capable of detecting movement of a sample solution between the two temperature zones; a pair of liquid delivery mechanisms that allow the sample solution to move between the two temperature zones and that are configured to be open to atmospheric pressure when liquid delivery stops; a substrate on which the chip for nucleic acid amplification according to claim 2 can be placed; and a control mechanism that controls driving of each liquid delivery mechanism by receiving an electrical signal from the fluorescence detector relating to movement of the sample solution from the control mechanism; the device being capable of performing real-time PCR by measuring fluorescence intensity for each thermal cycle.

Claims (35)

1. A reciprocal-flow-type nucleic acid amplification device comprising:

(a) heaters capable of forming a denaturation temperature zone and an extension/annealing temperature zone;

(b) at least one fluorescence detector capable of detecting movement of a sample solution between the two temperature zones;

(c) a substrate on which a chip for nucleic acid amplification can be placed, wherein the chip for nucleic acid amplification comprises at least one microchannel contacted to each temperature zone, wherein the at least one microchannel comprises:

(i) curved-channel portions each set in a denaturation temperature zone and an extension/annealing temperature zone of the nucleic acid amplification device,

(ii) a linear intermediate-channel portion connecting the curved-channel portions, and

(iii) connections at both ends of the microchannel;

(d) at least one liquid delivery mechanism selected from a microblower and a fan, which is connected to at least one of the connections of the microchannel, that allows the sample solution to move between the two temperature zones and that is configured to be open to atmospheric pressure when liquid delivery stops; and

(e) a control mechanism that controls driving of the at least one liquid delivery mechanism by receiving an electrical signal relating to movement of the sample solution from the at least one fluorescence detector,

wherein the device is configured:

to perform real-time PCR by measuring fluorescence intensity for each thermal cycle,

so that the at least one liquid delivery mechanism selected from a microblower and a fan applies or reduces pressure in the microchannel by blowing air in order to reciprocally move the sample solution between the two temperature zones, and

so that liquid delivery stops immediately after air blowing is stopped, when or immediately before the solution has reached a precise position on each temperature zone.

2. The reciprocal-flow-type nucleic acid amplification device according to claim 1 , wherein the nucleic acid amplification device comprises a pair of liquid delivery mechanisms selected from microblowers and fans, which are connected to the connections of the microchannel, that allow the sample solution to move between the two temperature zones and that are configured to be open to atmospheric pressure when liquid delivery stops.

3. A nucleic acid amplification method comprising the following steps:

step 1: placing a chip for nucleic acid amplification according to claim 1 on the substrate of the device of claim 1 in such a manner that the denaturation temperature zone includes at least one curved-microchannel portion and the extension/annealing temperature zone includes at least one curved-microchannel portion;

step 2: introducing a sample solution into the microchannel;

step 3: connecting a pair of liquid delivery mechanisms according to claim 1 to the liquid delivery mechanism connections at both ends of the microchannel; and

step 4: reciprocating the sample solution between the two curved-microchannel portions of the microchannel by the liquid delivery mechanisms to perform thermal cycling, and simultaneously measuring the fluorescence intensity of the sample solution and confirming the movement of the sample solution for each thermal cycle using the at least one fluorescence detector in the intermediate-microchannel portion to perform the nucleic acid amplification method,

wherein the nucleic acid amplification method is selected from the group consisting of polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), one-step RT-PCR, multiplex RT-PCR, real-time PCR, and real-time RT-PCR.

4. The nucleic acid amplification method according to claim 3 , wherein the measurement of fluorescence intensity is performed by simultaneously measuring two or more fluorescent wavelengths to simultaneously measure the nucleic acid amplification of multiple genes in one microchannel.

5. The nucleic acid amplification method according to claim 3 , wherein the initial concentration of a nucleic acid in the sample is determined using a calibration curve obtained by plotting Ct values as a function of concentration for a number of standards having known concentrations of the nucleic acid.

6. The nucleic acid amplification method according to claim 3 , wherein the chip comprises two or more microchannels, wherein the operation of liquid delivery through each of the microchannels can be independently controlled.

7. The nucleic acid amplification method according to claim 3 , the method further comprising:

connecting an end of a filtered pipette tip of a micropipette to one of the connections so as to introduce a sample solution into the microchannel;

removing the micropipette with the pipette tip being connected to the connection, and

then connecting the pipette tip to one of the liquid delivery mechanisms.

8. The nucleic acid amplification method according to claim 3 , wherein the volume of the sample solution introduced into the microchannel is in the range of 5 μL to 50 μL.

9. The nucleic acid amplification method according to claim 4 , wherein the initial concentration of a nucleic acid in the sample is determined using a calibration curve obtained by plotting Ct values as a function of concentration for a number of standards having known concentrations of the nucleic acid.

10. The nucleic acid amplification method according to claim 4 , wherein the chip comprises two or more microchannels, wherein the operation of liquid delivery through each of the microchannels can be independently controlled.

11. The nucleic acid amplification method according to claim 10 , the method further comprising:

connecting an end of a filtered pipette tip of a micropipette to one of the connections so as to introduce a sample solution into at least one of the microchannels;

removing the micropipette with the pipette tip being connected to the connection, and

then connecting the pipette tip to one of the liquid delivery mechanisms.

12. The nucleic acid amplification method according to claim 11 , wherein the volume of the sample solution introduced into the at least one microchannel is in the range of 5 μL to 50 μL.

Assignments (6)
ASSIGNEE ADDRESS CHANGE Recorded Oct 2, 2024
From: KYORIN PHARMACEUTICAL CO., LTD.
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 069109/0377 →
MERGER Recorded Nov 13, 2023
From: KYORIN PHARMACEUTICAL CO., LTD.
To: KYORIN HOLDINGS, INC.
Reel/Frame 065545/0869 →
CHANGE OF NAME Recorded Nov 13, 2023
From: KYORIN HOLDINGS, INC.
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 065545/0960 →
MERGER Recorded Dec 12, 2017
From: JTAS INC.
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 044841/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
To: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY; JTAS INC.
Reel/Frame 043683/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: NAGAI, HIDENORI; FURUTANI, SHUNSUKE; HAGIHARA, YOSHIHISA; FUCHIWAKI, YUSUKE
To: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
Reel/Frame 040760/0775 →
Priority Claims (1)
JP JP2014-140758 · Jul 8, 2014 · national
Continuity (1)
Related Publication 20170130261A1 · May 11, 2017